Benetatos et al. [53] evaluated the aberrant promoter methylation of MEG3 in 42 AML patients, and found that MEG3 hypermethylation was present in 47.6% AML cases and might be associated with significantly reduced overall survival rate in these patients [53]. The gene discussed is MEG3; the disease is acute myeloid leukemia.